Qualiclinic Kft.

Budapest 33 trials 9 recruiting

33 Registered trials

9 Currently recruiting

Organisation

Qualiclinic Kft.

Location

Budapest, Hungary

Identifier

ORG-100043006

Address

Tuzer Utca 39, 1134, Hungary

Departments

-
#3103
2108
3103
40081
4013
Department of Rheumatology
HU10008
N/A
NA
Qualiclinic Egeszsegugyi Szolgaltato es Kutatasszervezo Kft.
Qualiclinic Kft.
Reumatologia
Rheumatology

Clinical trials at this site (33)

Search interface

A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflamma… Pending

2025-522076-85-00 Rheumatoid arthritis 4
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety … Recruiting

2024-520098-12-00 Cutaneous Lupus Erythematosus 4 2026-02-16
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis Recruiting

2025-520721-21-00 Rheumatoid Arthritis 4 2025-10-20
A randomized, two-period crossover study to demonstrate the comparability of pharmacokinetics of subcutaneous ianalumab between 2mL auto-inj… Recruiting

2023-508996-35-00 Rheumatoid Arthritis 4 2024-11-18
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E… Recruiting

2025-523552-31-00 Systemic Lupus Erythematosus 5 2026-05-07
A study to learn about the effectiveness and safety of different doses of JNJ-88545223 in people with active psoriatic arthritis Recruiting

2025-523141-10-00 Active Psoriatic Arthritis 4 2026-03-20
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Psoriatic Arthritis 5 2025-06-26
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-experienced Participants with Active Psoriatic Arthritis Recruiting

2024-517284-23-00 Active Psoriatic Arthritis 5 2025-04-23
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting

2023-505929-14-00 Systemic Lupus Erythematosus 5 2024-05-21
Weight loss in people living with overweight or obesity and type 2 diabetes following treatment with cagrilintide Ended

2024-519531-41-00 Overweight and obesity 5 2025-10-31
A Study to Compare Different Doses of RO7795081 with a Placebo or Semaglutide in People with Type 2 Diabetes Ended

2024-520322-11-00 Type 2 Diabetes Mellitus (T2D) 4 2025-09-29
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended

2023-509239-19-00 Active Psoriatic Arthritis 5 2025-04-03
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended

2024-511738-11-00 Psoriatic arthritis 5 2024-12-18
REIMAGINE 5: A research study to see how much CagriSema (1.0 mg once weekly) lowers blood sugar and body weight compared to tirzepatide (5 m… Ended

2023-509600-15-00 Type 2 Diabetes 5 2024-10-18
Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended

2023-508498-97-00 Systemic Lupus Erythematosus 5 2023-02-03
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended

2023-506256-25-00 Active Psoriatic Arthritis 5 2021-10-20
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended

2023-504734-21-00 Psoriatic arthritis (PsA) 5 2021-08-30
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended

2023-504716-15-00 Psoriatic Arthritis 6 2021-08-06
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth… Ended

2022-501017-31-00 Rheumatoid arthritis 5 2016-05-10